Literature DB >> 17462692

Myristoylation signal transfer from the large to the middle or the small HBV envelope protein leads to a loss of HDV particles infectivity.

Georges Abou-Jaoudé1, Sonia Molina, Patrick Maurel, Camille Sureau.   

Abstract

A myristate linked to the N-terminus of the large hepatitis B virus (HBV) envelope protein was found to be required for infectivity of the hepatitis delta virus (HDV). Myristoylation of the large HBV envelope protein being known as indispensable for HBV infectivity, this result further demonstrates the similarities between the HBV and HDV entry pathways. In addition, the transfer of the N-myristoylation signal from the large to the middle or the small HBV envelope protein led in both cases to a loss of HDV infectivity. Hence, it is suggested that viral entry could depend on a physical link, or a spatial association, between the N-terminal receptor-binding polypeptide of the large protein and the myristoyl anchor linked to glycine-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462692     DOI: 10.1016/j.virol.2007.03.030

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23

2.  A function essential to viral entry underlies the hepatitis B virus "a" determinant.

Authors:  Jessica Salisse; Camille Sureau
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

3.  The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent.

Authors:  Yann Le Duff; Matthieu Blanchet; Camille Sureau
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

4.  Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.

Authors:  Sonia Molina; Valerie Castet; Lydiane Pichard-Garcia; Czeslaw Wychowski; Eliane Meurs; Jean-Marc Pascussi; Camille Sureau; Jean-Michel Fabre; Antonio Sacunha; Dominique Larrey; Jean Dubuisson; Joliette Coste; Jane McKeating; Patrick Maurel; Chantal Fournier-Wirth
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 5.  Animal models of chronic hepatitis delta virus infection host-virus immunologic interactions.

Authors:  Rafael Aldabe; Lester Suárez-Amarán; Carla Usai; Gloria González-Aseguinolaza
Journal:  Pathogens       Date:  2015-02-12

6.  Inhibition of N-myristoyltransferase1 affects dengue virus replication.

Authors:  San Suwanmanee; Yuvadee Mahakhunkijcharoen; Sumate Ampawong; Pornsawan Leaungwutiwong; Dorothée Missé; Natthanej Luplertlop
Journal:  Microbiologyopen       Date:  2019-03-07       Impact factor: 3.139

7.  The N-Terminus Makes the Difference: Impact of Genotype-Specific Disparities in the N-Terminal Part of The Hepatitis B Virus Large Surface Protein on Morphogenesis of Viral and Subviral Particles.

Authors:  Bingfu Jiang; Xingjian Wen; Qingyan Wu; Daniela Bender; Gert Carra; Michael Basic; Alica Kubesch; Kai-Henrik Peiffer; Klaus Boller; Eberhard Hildt
Journal:  Cells       Date:  2020-08-13       Impact factor: 6.600

8.  Targeting the YXXΦ Motifs of the SARS Coronaviruses 1 and 2 ORF3a Peptides by In Silico Analysis to Predict Novel Virus-Host Interactions.

Authors:  Athanassios Kakkanas; Eirini Karamichali; Efthymia Ioanna Koufogeorgou; Stathis D Kotsakis; Urania Georgopoulou; Pelagia Foka
Journal:  Biomolecules       Date:  2022-07-29

9.  ATP5B Is an Essential Factor for Hepatitis B Virus Entry.

Authors:  Keiji Ueda; Yadarat Suwanmanee
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

10.  Posttranslational modifications and secretion efficiency of immunogenic hepatitis B virus L protein deletion variants.

Authors:  Baiba Niedre-Otomere; Ance Bogdanova; Ruta Bruvere; Velta Ose; Wolfram H Gerlich; Paul Pumpens; Dieter Glebe; Tatjana Kozlovska
Journal:  Virol J       Date:  2013-02-25       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.